



PRESS RELEASE

FOR IMMEDIATE RELEASE

DNAVISION SA CLOSED A 1 MILLION \$ NET IN CAPITAL INCREASE

Brussels, April 29th 2006 – **DNAVision** announced today that it has raised **\$ 1 million in capital increase**. In addition to the actual shareholders – **University of Brussels** and **Bio.be**, a subsidiary of **Institute of Pathology and Genetics**, two new investors have also subscribed to the capital round: **Sambrinvest** and **Technowal**, a subsidiary of **SRIW**.

Jean-Pol Detiffe, CEO of **DNAVision**, comments: "This capital increase should allow us to finance our operations until the end of 2009 and to develop our R&D projects in the field of pharmacogenetics and pharmacogenomics. This successful closing recognizes **DNAVision**'s achievements since its creation, less than two years ago. Going forward, we will continue to focus on providing DNA & RNA testing that improve pharmaceutical research and patient care by the use of personalized medicine."

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. **DNAVision** offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment. **DNAVision** is a spin-off of Free University of Brussels and Institute of Pathology and Genetics. **DNAVision** is the first full-service pharmacogenomic laboratory to be ISO17025 accredited. More information on **DNAVision**'s service portfolio can be found on www.dnavision.be

Further information:

Jean-Pol Detiffe

DNAVision

Tel. +32 71 378 527

Fax. +32 71 378 501

jp.detiffe@dnavision.be

www.dnavision.be